Abstract
Background:
Gefitinib and/or erlotinib-induced hepatotoxicity sometimes lead to treatment failure in EGFR mutation-positive patients with non-small cell lung cancer (NSCLC), even though the therapeutic effect is evident.
Cases:
Here, we report three postoperative NSCLC patients with recurrences who experienced severe hepatotoxicity while receiving gefitinib and/or erlotinib treatment but could be safely switched to afatinib treatment.
Conclusion:
Afatinib could be a well-tolerated EGFR-TKI that could be chosen for its relatively low hepatotoxicity, which is attributable to its having a different metabolic mechanism compared to other EGFR-TKIs.
MeSH terms
-
Adenocarcinoma / diagnostic imaging
-
Adenocarcinoma / drug therapy
-
Adenocarcinoma / genetics
-
Adenocarcinoma of Lung
-
Afatinib
-
Aged
-
Carcinoma, Non-Small-Cell Lung / diagnostic imaging
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / genetics
-
Erlotinib Hydrochloride / adverse effects
-
Female
-
Gefitinib
-
Genes, erbB-1
-
Humans
-
Liver / drug effects
-
Lung Neoplasms / diagnostic imaging
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / genetics
-
Male
-
Middle Aged
-
Mutation
-
Protein Kinase Inhibitors / therapeutic use
-
Quinazolines / adverse effects
-
Quinazolines / therapeutic use*
-
Tomography, X-Ray Computed
Substances
-
Protein Kinase Inhibitors
-
Quinazolines
-
Afatinib
-
Erlotinib Hydrochloride
-
Gefitinib